[article]
Titre : |
Clinical Validation of the Autism Behavior Inventory: Caregiver-Rated Assessment of Core and Associated Symptoms of Autism Spectrum Disorder |
Type de document : |
Texte imprimé et/ou numérique |
Auteurs : |
Abigail BANGERTER, Auteur ; Seth NESS, Auteur ; David LEWIN, Auteur ; Michael G. AMAN, Auteur ; Anna J. ESBENSEN, Auteur ; Matthew S GOODWIN, Auteur ; Geraldine DAWSON, Auteur ; Robert HENDREN, Auteur ; Bennett L. LEVENTHAL, Auteur ; Fred SHIC, Auteur ; Mark OPLER, Auteur ; Kai Fai HO, Auteur ; Gahan PANDINA, Auteur |
Article en page(s) : |
p.2090-2101 |
Langues : |
Anglais (eng) |
Mots-clés : |
Assessment Autism spectrum disorder Caregiver-reported outcomes Clinical trials Rating scales and instruments hold company stocks/stock options. Anna Esbensen has consulted with Roche on outcome measures in Down syndrome and ProPhase LLC. Robert Hendren received reimbursement for consultation from Janssen Research & Development, LLC. Michael Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for AMO Pharma, Bracket, CogState, Inc., CogState Clinical Trials, Ltd., Coronado Biosciences, Forest Research, Hoffman-La Roche, Lumos Pharma, MedAvante, Inc., Ovid Therapeutics ProPhase LLC, Supernus Pharmaceuticals, Zynerba Pharmaceuticals, and Yamo Pharmaceuticals. He receives royalties from Slosson Educational Publications. Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, LabCorp, and Akili, Inc., a consultant to Roche has received grant funding from Janssen Research and Development, LLC and PerkinElmer and, receives royalties from Guilford Press and Oxford University Press. |
Index. décimale : |
PER Périodiques |
Résumé : |
There is a need for measures to track symptom change in autism spectrum disorder (ASD). We conducted a validation study on a revised version of the Autism Behavior Inventory (ABI), and a short form (ABI-S). Caregivers of individuals (6-54 years) with confirmed diagnoses of ASD (N?=?144) completed the ABI and other rating scales at 4 time points. Scale consistency for each domain, 3-5 day test-retest reliability, and construct validity, determined by comparison to pre-specified scales, were all good. Change in the ABI was congruent with changes in other instruments. Collectively, results suggest incipient suitability of the ABI as a measure of changes in core and associated symptoms of ASD.Trial Registration NCT02299700. |
En ligne : |
http://dx.doi.org/10.1007/s10803-019-03965-7 |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=425 |
in Journal of Autism and Developmental Disorders > 50-6 (June 2020) . - p.2090-2101
[article] Clinical Validation of the Autism Behavior Inventory: Caregiver-Rated Assessment of Core and Associated Symptoms of Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Abigail BANGERTER, Auteur ; Seth NESS, Auteur ; David LEWIN, Auteur ; Michael G. AMAN, Auteur ; Anna J. ESBENSEN, Auteur ; Matthew S GOODWIN, Auteur ; Geraldine DAWSON, Auteur ; Robert HENDREN, Auteur ; Bennett L. LEVENTHAL, Auteur ; Fred SHIC, Auteur ; Mark OPLER, Auteur ; Kai Fai HO, Auteur ; Gahan PANDINA, Auteur . - p.2090-2101. Langues : Anglais ( eng) in Journal of Autism and Developmental Disorders > 50-6 (June 2020) . - p.2090-2101
Mots-clés : |
Assessment Autism spectrum disorder Caregiver-reported outcomes Clinical trials Rating scales and instruments hold company stocks/stock options. Anna Esbensen has consulted with Roche on outcome measures in Down syndrome and ProPhase LLC. Robert Hendren received reimbursement for consultation from Janssen Research & Development, LLC. Michael Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for AMO Pharma, Bracket, CogState, Inc., CogState Clinical Trials, Ltd., Coronado Biosciences, Forest Research, Hoffman-La Roche, Lumos Pharma, MedAvante, Inc., Ovid Therapeutics ProPhase LLC, Supernus Pharmaceuticals, Zynerba Pharmaceuticals, and Yamo Pharmaceuticals. He receives royalties from Slosson Educational Publications. Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, LabCorp, and Akili, Inc., a consultant to Roche has received grant funding from Janssen Research and Development, LLC and PerkinElmer and, receives royalties from Guilford Press and Oxford University Press. |
Index. décimale : |
PER Périodiques |
Résumé : |
There is a need for measures to track symptom change in autism spectrum disorder (ASD). We conducted a validation study on a revised version of the Autism Behavior Inventory (ABI), and a short form (ABI-S). Caregivers of individuals (6-54 years) with confirmed diagnoses of ASD (N?=?144) completed the ABI and other rating scales at 4 time points. Scale consistency for each domain, 3-5 day test-retest reliability, and construct validity, determined by comparison to pre-specified scales, were all good. Change in the ABI was congruent with changes in other instruments. Collectively, results suggest incipient suitability of the ABI as a measure of changes in core and associated symptoms of ASD.Trial Registration NCT02299700. |
En ligne : |
http://dx.doi.org/10.1007/s10803-019-03965-7 |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=425 |
|